Veloxis Pharmaceuticals Agrees to Pay Over $46M to Resolve Criminal and Civil Liability
RedMap Risk Score
80/100
CRITICAL RISK
Risk Signal Summary
Veloxis Pharmaceuticals Inc. has agreed to pay over $46 million to resolve allegations of kickbacks to healthcare providers to induce prescriptions of Envarsus XR. The settlement includes a deferred prosecution agreement and penalties for violating the Anti-Kickback Statute in Cary, North Carolina.
Why This Matters
Governance and compliance anomalies in organizations managing public funds or charitable assets directly affect donors, beneficiaries, and taxpayers. The risk indicators identified in this report warrant further scrutiny by regulators, donors, and oversight bodies.
Create a free account
Unlimited access to all articles · No daily limit
No credit card · Instant access
Multiple related entities detected
🔒 Veloxis Pharmaceuticals Inc. has potential risk indicators with connected organizations. Unlock full network analysis.
Sign up free to unlock →Disclaimer: This report identifies risk indicators and unusual financial patterns based on publicly available IRS Form 990 data and government enforcement records. It does not assert fraud, criminal conduct, or legal violations. All findings are for informational purposes only and should not be construed as legal or financial advice.
Share this finding
You just analyzed Veloxis Pharmaceuticals Inc. — Risk Score 80/100, $46.0M involved. Share this with your network.
Post text is pre-formatted for maximum reach — you can edit before posting.
Discover more risk signals across the USA.